EGFR and colorectal carcinoma: To dissect the contribution of EGFR blockade to the bioactivity of DbαEGFR-scTRAIL we used the EGFR-positive Caco-2 CRC cell line, which harbors mutations in APC, p53, and SMAD4 but is wild-type for the MAPK and PI3K pathways [16].